Bone Health Stocks: 5 Names in Biotech's $20B Market

Bone health is biotech’s most under-covered market. Amgen’s Evenity and Prolia do a combined $6.5 billion a year treating osteoporosis and bone loss (Amgen 2025 full-year results), yet the sector gets a fraction of the attention of oncology or neuroscience. An aging global population is the tailwind nobody talks about: every year, 2 million osteoporosis-related fractures occur in the US alone, and knee osteoarthritis disables 31 million Americans with no disease-modifying drug. The incumbents print money; the next wave is anabolic bone-builders, rare-bone gene therapies, and the DMOAD that has eluded the industry for three decades. Here are five bone-health stocks ranked by catalyst timing and risk-reward.

1. Mirum Pharmaceuticals (MIRM, $97.46, $5.94B market cap): Buy

Catalyst: zilurgisertib FOP PDUFA, September 26, 2026

Mirum in-licensed zilurgisertib from Incyte in May 2026 and walks into a Priority Review PDUFA on September 26. The drug is an ALK2 inhibitor for fibrodysplasia ossificans progressiva, the ultra-rare disease where muscle and connective tissue progressively turn into bone. PROGRESS Phase 2 trial (NCT05090891) data were presented at ENDO 2026 as a late-breaker, and while the full dataset has not been published in a journal, the FDA accepted the NDA under Priority Review, which signals the data were strong enough to warrant an accelerated timeline.

The competitive picture changed in August 2026 when Regeneron’s Pasatru (garetosmab) became the first FDA-approved FOP therapy (FDA approval announced August 2026). Zilurgisertib is structurally different: it inhibits ALK2, the receptor that drives heterotopic ossification, while garetosmab blocks the Activin A ligand upstream. If zilurgisertib is approved, Mirum gets a second commercial rare-disease drug alongside LIVMARLI, with peak sales estimates in the $200-400 million range. The market is pricing in approval: MIRM traded at $55 before the Incyte deal and has nearly doubled since. At $5.94 billion for a company with one commercial drug and one pending PDUFA, the multiple is rich for rare disease. But the September 26 catalyst is 22 days away, and Priority Review approvals rarely miss.

Verdict: Buy into the PDUFA. A second approved rare-disease drug validates the platform; a CRL drops the stock 30%.

2. BioMarin Pharmaceutical (BMRN, $64.67, $12.5B market cap): Hold

Catalysts: vosoritide sNDA PDUFA February 28, 2027; Alesta/Strensiq hypophosphatasia franchise

BioMarin is the closest thing to a bone-health pure play among large-cap biotechs. VOXZOGO (vosoritide) for achondroplasia generated $858 million in 2025 revenue under accelerated approval. The sNDA to convert to full approval, accepted July 2026 with a February 28, 2027 PDUFA, is supported by the largest body of long-term data in achondroplasia history: adult height outcomes, body proportionality, and spinal morphology across multiple studies (the PDUFA primer). A full approval removes the postmarketing requirement overhang and opens the label for younger patients.

The enzyme replacement franchise adds ballast. BioMarin acquired Inozyme in 2025, bringing INZ-701 (ENPP1 deficiency) into a portfolio that already includes Alesta (asfotase alfa) and Strensiq for hypophosphatasia (the Inozyme acquisition). Bone enzymes are sticky, high-margin rare-disease revenue with minimal competition.

At $12.5 billion and 12x forward sales, BMRN is not cheap, but the catalyst calendar is stacked: vosoritide full approval in February, potential INZ-701 BLA filing, and the achondroplasia franchise expanding into hypochondroplasia and other skeletal dysplasias. The risk is that full approval of vosoritide is already priced in; the stock has rallied 15% since the sNDA acceptance.

Verdict: Hold. The catalysts are real but the multiple leaves limited upside. Buy on any weakness below $58.

3. Organogenesis Holdings (ORGO, $1.74, $223.9M market cap): Speculative Buy

Catalyst: ReNu knee OA BLA PDUFA, April 24, 2027

This is the highest-risk, highest-reward name on the list. Organogenesis filed a Biologics License Application for ReNu, a cryopreserved amniotic suspension allograft, for symptomatic knee osteoarthritis pain. The FDA accepted the BLA in July 2026 and set an April 24, 2027 PDUFA (ReNu BLA acceptance coverage). If approved, ReNu would be the first non-surgical biologic therapy for a disease affecting 31 million Americans, projected to exceed 34 million by 2027.

The DMOAD graveyard is deep. Every company that has tried to modify osteoarthritis disease progression has failed: tissueGene-C (Kolon), sprifermin (Merck KGaA), lorecivivint (Biosplice), tanezumab (Pfizer). Organogenesis is not claiming disease modification; it is targeting pain management, which is a lower regulatory bar. The BLA is supported by a randomized, saline-controlled trial, and the FDA accepted it for review rather than issuing a refuse-to-file letter, which is a meaningful signal for a $224 million market cap company.

At 12 cents on the dollar relative to the knee OA market opportunity, ORGO is pricing ReNu at near-zero. If approved, the stock re-rates to $500-800 million market cap (a 2-3x from here). If the FDA issues a CRL, Organogenesis still has its wound-care and surgical biologics business generating roughly $400 million in annual revenue, so the floor is not zero.

Verdict: Speculative Buy. The binary is favorable: limited downside from existing revenue, 2-3x upside on approval. Position size at 1-2% of a biotech portfolio.

4. Regeneron Pharmaceuticals (REGN, $794.19, $81.8B market cap): Hold

Catalyst: Pasatru (garetosmab) FOP approval, August 2026 (already reflected)

Regeneron’s Pasatru became the first FDA-approved therapy for FOP in August 2026, reducing new heterotopic ossification and clinician-assessed disease flare-ups in adults. The approval is clinically meaningful for the ~800 US FOP patients, but financially immaterial for an $81.8 billion company. Even at a $500,000 annual price, Pasatru generates $400 million in peak revenue; less than half a percent of Regeneron’s $14 billion revenue base. EYLEA alone does $9 billion.

The stock did not move on the approval, and it should not have. Regeneron is an oncology and retinal disease company; FOP is a rounding error on the pipeline slide. Investors looking for bone-health exposure should own MIRM or BMRN, not REGN. The value of the Pasatru approval is as a validation signal for the ALK2/Activin A pathway, which benefits Mirum’s zilurgisertib read-through more than it benefits Regeneron shareholders (see the rare-disease catalysts ranked piece).

Verdict: Hold. Own REGN for Dupixent and the oncology pipeline, not for FOP.

5. Amgen (AMGN, $432.42, $233.8B market cap): Hold

Incumbent: Evenity ($2.1B, 2025) and Prolia ($4.4B, 2025)

Amgen is the bone-health incumbent, and the numbers tell the story. Evenity (romosozumab), the anabolic bone-builder, grew 34% in 2025 to $2.1 billion. Prolia (denosumab), the antiresorptive, did $4.4 billion but grew only 1% as US biosimilars launched. The combined $6.5 billion franchise is the baseline every new bone drug has to beat on efficacy, convenience, or both.

The problem for Amgen investors is that this $6.5 billion is not growing. Prolia biosimilar erosion accelerates in 2026; Evenity volume growth offsets some of it, but the net bone-health revenue line is flat to slightly declining. Amgen’s growth is coming from obesity (MariTide Phase 3), oncology (LUMAKRAS, BLINCYTO), and inflammation (TEZSPIRE, OTEZLA), not from bone. At $233.8 billion market cap and 6x forward sales, AMGN is a value play, not a bone-health catalyst trade.

Verdict: Hold. The bone franchise is a cash cow, not a growth driver. Buy AMGN for the obesity pipeline, not for Evenity.

Risks

Knee osteoarthritis has defeated every drug that has tried to modify it, and ReNu’s amnion-derived mechanism has no precedent for FDA approval. That is the risk that matters here, because ReNu is the entire thesis for Organogenesis. FOP adds a market-size problem: with fewer than 1,000 US patients, two approved drugs (Pasatru and, if approved, zilurgisertib) could split a market too small to support both at premium pricing. The rest is structural. Amgen and Regeneron are mega-caps where bone drugs are immaterial to the stock, while the pure-plays (MIRM, BMRN, ORGO) carry binary risk that does not diversify away in a concentrated portfolio.

Verdict

Mirum is the highest-conviction name: September 26 PDUFA, Priority Review, and a read-through from Regeneron’s approval that validates the ALK2 pathway. The stock has run, but the catalyst is binary and imminent. BioMarin is the safest name: diversified rare-disease revenue, a February 2027 vosoritide full-approval catalyst, and an enzyme replacement franchise that prints cash. Organogenesis is the highest-upside name but also the riskiest: a $224 million micro-cap with an April 2027 PDUFA that could triple the stock or halve it. Regeneron and Amgen are Holds; the bone drugs are immaterial, own them for other reasons. Ranked: MIRM (Buy), BMRN (Hold), ORGO (Speculative Buy), REGN (Hold), AMGN (Hold).